AMRI makes a promotion in Singapore
Takeshi Yura becomes senior director of drug discovery services
In this expanded role, Yura will take overall responsibility for site management, which includes leadership of the AMRI Singapore Research Centre's chemistry, biology and r&d operations.
Yura will replace Raymond Yeung, who has been managing director of the site from 2007.
Initially joining the Singapore subsidiary in January as assistant director of medicinal chemistry, Yura has more than 22 years of experience in discovery chemistry, project management and business development.
Prior to joining AMRI, he was a director at Dishman Japan, responsible for sales and business development activities. Before this he was discovery chemistry research head at Pfizer Japan, and section head of medicinal chemistry at Bayer Yakuhin.
‘Since joining us earlier this year, we have been impressed with the extent of scientific and business leadership Dr Yura has brought to AMRI and look forward to the additional contributions he will bring to the company in this new role,’ said Bruce Sargent, senior vp of drug discovery at AMRI.
You may also like
Research & Development
€2.5m boost for SensABLATE to revolutionise real-time lung cancer treatment
The next-generation AI and photonics system is designed to provide instant intraoperative confirmation during lung cancer ablation and aims to improve precision, reduce repeat procedures and enhance patient outcomes
Regulatory
FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment
The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Research & Development
Vivan Therapeutics and MRC LMS launch partnership to study how KRAS mutations, diabetes and diet shape cancer drug response
The new collaboration will investigate how KRAS mutations and metabolic conditions such as diabetes influence chemotherapy effectiveness, using high-throughput in vivo “fly avatar” models
Research & Development
Gates Foundation awards Keltic Pharma $1.3 million for malaria drug research
The University of Glasgow spin-out's malaria programme is moving towards IND enablement within the next 12 months and is designed to deliver a single-dose cure — a potential breakthrough in efforts to combat one of the world’s most lethal diseases